top of page
16699400673464_edited.jpg

Latest News

Congratulations to former member Ms. Chien-Yu Chou and Ph.D. student Zhi-Qin Li on publishing research in ACS Omega

Latest Publications

The antitumor effects elicited by immune checkpoint inhibitors (ICIs) have transformed cancer treatments. However, severe immune-related adverse events (irAEs) resulting from these treatments have restricted the application of ICIs. To overcome the adverse events, we developed a tumor lesion-selective pro-PD-1Ig that is activated by proteases overexpressed in tumors. We genetically linked albumin to the N-terminus of a modified PD-1Ig (termed mutPD-1Ig hereafter) via an MMP substrate sequence to form Alb-hinge-mutPD-1Ig. We demonstrate that the binding activity of nondigested Alb-hinge-mutPD-1Ig is approximately 11-folds lower than mutPD-1Ig. However, digestion by type IV collagenase restored the binding activity of Alb-hinge-mutPD-1Ig to a level comparable to that of native mutPD-1Ig. In order to enhance the masking efficiency of Alb-mutPD-1Ig, we simulated the effects of diverse MMP substrate linkers for connecting albumin and PD-1 at various starting positions by bioinformatics tools. Our validation experiments indicate Alb-hinge-mutPD-1Ig displayed the best masking efficiency among all simulated constructs. Our study suggests that albumin may be best applicable to mask a target protein whose binding motif is centralized and in the proximity of the N-terminus of the protein.

About our Lab

In our laboratory, we apply the knowledge and the methods of immunology to study human diseases and develop new therapeutic drugs. In particular, we are interested in studying the pathogenesis and therapy for non-alcoholic fatty liver disease. We are also interested in developing second-generation therapeutic proteins that act only in the lesion sites. Several therapeutic proteins have been developed and are currently tested for inflammatory diseases and cancers in cell and animal studies.

bottom of page